Essentials
- •
The comparative efficacy and safety of antiplatelet agents in ‘real life’ is not clear.
- •
We recruited acute coronary syndrome patients receiving percutaneous coronary intervention.
- •
At 1‐year follow‐up, prasugrel offers better anti‐ischemic protection than clopidogrel.
- •
Prasugrel and ticagrelor are accompanied by more frequent bleeding events.